{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:46:20Z","timestamp":1762875980793,"version":"3.40.5"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.jhep.2018.05.012","type":"journal-article","created":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T12:27:01Z","timestamp":1526905621000},"page":"275-277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Exploring new treatment paradigms for alcoholic hepatitis by extrapolating from NASH and cholestasis"],"prefix":"10.1016","volume":"69","author":[{"given":"Thoetchai (Bee)","family":"Peeraphatdit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4095-8144","authenticated-orcid":false,"given":"Douglas A.","family":"Simonetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay H.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2018.05.012_b0005","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0016-5085(78)90401-8","article-title":"Corticosteroid therapy of alcoholic hepatitis","volume":"75","author":"Maddrey","year":"1978","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.05.012_b0010","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","article-title":"Prednisolone or pentoxifylline for alcoholic hepatitis","volume":"372","author":"Thursz","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2018.05.012_b0015","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cgh.2013.06.013","article-title":"Alcoholic hepatitis: current challenges and future directions","volume":"12","author":"Singal","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2018.05.012_b0020","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1172\/JCI60777","article-title":"IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice","volume":"122","author":"Petrasek","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2018.05.012_b0025","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.coph.2017.09.008","article-title":"Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases","volume":"37","author":"Malhi","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jhep.2018.05.012_b0030","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","article-title":"Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats","volume":"59","author":"Verbeke","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.012_b0035","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2018.05.012_b0040","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2018.05.012_b0045","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2018.05.012_b0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151829","article-title":"Bile acids and dysbiosis in non-alcoholic fatty liver disease","volume":"11","author":"Mouzaki","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2018.05.012_b0055","article-title":"The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids","author":"Puri","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.012_b0060","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1515\/jpem-2012-0253","article-title":"A decrease in fasting FGF19 levels is associated with the development of non-alcoholic fatty liver disease in obese adolescents","volume":"25","author":"Wojcik","year":"2012","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.jhep.2018.05.012_b0065","unstructured":"FDA. FDA adds Boxed Warning to highlight correct dosing of Ocaliva (obeticholic acid) for patients with a rare chronic liver disease; 2018."},{"key":"10.1016\/j.jhep.2018.05.012_b0070","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.27198","article-title":"Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification","volume":"60","author":"Ahn","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.012_b0075","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.95354","article-title":"Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis","volume":"2","author":"Greuter","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.jhep.2018.05.012_b0080","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator\u2212activated receptor\u2212\u03b1 and \u2212\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.05.012_b0085","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial","author":"Loomba","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.012_b0090","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.05.012_b0095","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1471-230X-14-166","article-title":"Long term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease","volume":"14","author":"Haflidadottir","year":"2014","journal-title":"BMC Gastroenterol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818320580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818320580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T04:15:26Z","timestamp":1571372126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827818320580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0168827818320580"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2018.05.012","relation":{},"ISSN":["0168-8278"],"issn-type":[{"type":"print","value":"0168-8278"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring new treatment paradigms for alcoholic hepatitis by extrapolating from NASH and cholestasis","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2018.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2018.03.031","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}